Details of the Drug Combination

General Information of Drug Combination (ID: DCBPQE0)

Drug Combination Name
Indazole derivative 5 Arfolitixorin
Indication
Disease Entry Status REF
Carcinoma Investigative [1]
Component Drugs Indazole derivative 5   DMM1I8R Arfolitixorin   DMIXMYK
Small molecular drug Small molecular drug
2D MOL 2D MOL
3D MOL 3D MOL
High-throughput Screening Result Testing Cell Line: RXF 393
Zero Interaction Potency (ZIP) Score: 13.14
Bliss Independence Score: 14.45
Loewe Additivity Score: 14.69
LHighest Single Agent (HSA) Score: 14.78

Molecular Interaction Atlas of This Drug Combination

Molecular Interaction Atlas (MIA)
Indazole derivative 5 Interacts with 2 DTT Molecule(s)
DTT Name DTT ID UniProt ID Mode of Action REF
ABL T315I mutant (ABL T315I) TTZJTWA ABL1_HUMAN Inhibitor [3]
Fusion protein Bcr-Abl T315I mutant (Bcr-Abl T315I) TTIV39N BCR_HUMAN-ABL1_HUMAN Inhibitor [3]
------------------------------------------------------------------------------------
Indication(s) of Arfolitixorin
Disease Entry ICD 11 Status REF
Colorectal cancer 2B91.Z Phase 3 [2]

Test Results of This Drug Combination in Other Disease Systems

Indication DrugCom ID Cell Line Status REF
Adult T acute lymphoblastic leukemia DCQZN8Y MOLT-4 Investigative [4]
Astrocytoma DC4TXOY SNB-19 Investigative [4]
Clear cell renal cell carcinoma DC6ATLE 786-0 Investigative [4]
Glioblastoma DCA4SHD SNB-75 Investigative [4]
Renal cell carcinoma DCNN8TM SN12C Investigative [4]
Breast adenocarcinoma DCUDBPP MDA-MB-468 Investigative [1]
Carcinoma DCYLNE3 MCF7 Investigative [1]
Adenocarcinoma DCLFUE5 DU-145 Investigative [5]
High grade ovarian serous adenocarcinoma DCSP1YC OVCAR-8 Investigative [5]
High grade ovarian serous adenocarcinoma DCT9LBC NCI\\/ADR-RES Investigative [5]
------------------------------------------------------------------------------------
⏷ Show the Full List of 10 DrugCom(s)

References

1 Biologically active neutrophil chemokine pattern in tonsillitis.Clin Exp Immunol. 2004 Mar;135(3):511-8. doi: 10.1111/j.1365-2249.2003.02390.x.
2 ClinicalTrials.gov (NCT03750786) A Study to Compare the Efficacy of Arfolitixorin Versus Leucovorin in Combination With 5 Fluorouracil, Oxaliplatin, and Bevacizumab in Patients With Advanced Colorectal Cancer (AGENT). U.S. National Institutes of Health.
3 Bcr-Abl tyrosine kinase inhibitors: a patent review.Expert Opin Ther Pat. 2015 Apr;25(4):397-412.
4 Recurrent recessive mutation in deoxyguanosine kinase causes idiopathic noncirrhotic portal hypertension.Hepatology. 2016 Jun;63(6):1977-86. doi: 10.1002/hep.28499. Epub 2016 Mar 31.
5 Loss of function mutations in VARS encoding cytoplasmic valyl-tRNA synthetase cause microcephaly, seizures, and progressive cerebral atrophy.Hum Genet. 2018 Apr;137(4):293-303. doi: 10.1007/s00439-018-1882-3. Epub 2018 Apr 24.